Cell Therapeutics Inc. cti Announces Quarterly Management Conference Call.SEATTLE--(BW HealthWire)--April 6, 1999-- Senior Management to Update Progress in Portfolio Advancement Cell Therapeutics Inc. (cti) (Nasdaq:CTIC) today announced it has scheduled a quarterly conference call on Tuesday, April 13, 1999, at 4:30 p.m. Eastern (1:30 p.m. Pacific). Investors and analysts will hear an update by senior management on the company's progress in advancing cti's product portfolio and 1998 year-end financial results. To participate in the conference call, please dial 1-888-214-7570 from within the U.S., or +1-415-537-1806 from overseas. (Ask for the Cell Therapeutics Call.) In advance of the call, following is an outline of the product development milestones anticipated in second-quarter 1999: 1999 Second-Quarter Anticipated Milestones ------------------------------------------ APRIL ------------------------------------------ American Association of Cancer Research Meeting (Philadelphia). M.D. Anderson Cancer Center scientists present data demonstrating significant radiation sensitization sensitization /sen·si·ti·za·tion/ (sen?si-ti-za´shun) 1. administration of an antigen to induce a primary immune response. 2. exposure to allergen that results in the development of hypersensitivity. in ovarian cancer by PG-TXL (polyglutamate paclitaxel). Anti-Cancer Phase II Clinical Trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II . Initiation of second efficacy study for Apra(tm) (CT-2584) for soft tissue sarcomas. American Thoracic Society American Thoracic Society (ATS ), established in 1905, is an independently incorporated, international, educational and scientific society, serving its 18,000 members world-wide who are dedicated in respiratory and critical care medicine. Meeting (San Diego). ARDS Ards District (pop., 2001: 73,244), Northern Ireland. Formerly part of County Down, Ards was established as a district in 1973. Much of its land is devoted to crops and pasture. Newtownards, settled c. 1608 by Scots, is its administrative seat and manufacturing centre. clinical trial network (ARDSnet) and NHLBI NHLBI, n.pr See National Heart, Lung, and Blood Institute. update on ongoing study of LSF LSF Lisofylline, see there (tm) (lisofylline) for ARDS/ALI. MAY ------------------------------------------ American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. Meeting (Atlanta). Presentation of long-term followup data on patients from Phase I Apra (CT-2584) clinical studies. LSF Phase III Clinical Trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the . Completion of enrollment on LSF pivotal trial for induction chemotherapy for AML. LSF Clinical Results. NHLBI performs interim analysis on LSF pivotal Phase II/III trial for ARDS/ALI. JUNE ------------------------------------------ LSF Announcement. Release of results from NHLBI interim analysis recommendation. American Diabetes Association The American Diabetes Association, or the ADA, is an American health organization providing diabetes research, information and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of (San Diego). Report by leading diabetes researchers from City of Hope on regulation of fatty acid metabolism Fatty acids are an important source of energy for many organisms. Excess glucose can be stored efficiently as fat. Triglycerides yield more than twice as much energy for the same mass as do carbohydrates or proteins. as a novel approach to diabetes. Cell Therapeutics Inc. focuses on the discovery, development and commercialization of small molecule drugs that selectively regulate the metabolism of oxidized lipids and phospholipids relevant to the treatment of cancer and inflammatory and immune diseases. This news release, and additional information of interest, is available to all investors, prospective employees and patients at cti's web site at www.cticseattle.com This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of cti's products under development include risks associated with preclinical and clinical developments in the biotechnology industry in general and of cti's products under development in particular (including, without limitation, the potential failure of Apra, LSF, PG-TXL, SC-7 and related compounds to prove safe and effective for treatment of disease), determinations by regulatory, patent, and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing, and selling cti's products under development, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent registrations on Forms 10-K, 8-K, and 10-Q. http://www.businesswire.com/cnn/ctic.htm |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion